Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenformin with BRAF/MEK Inhibitors in Melanoma
NCT03026517Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2017
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of phenformin in melanoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Disease-free survival at 2 years and Safety and Tolerability. Started Jan 2017; status: completed.
02
Drugs
phenformin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03026517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03026517.